← Leaderboards
Harris Goldstein
Thomas Jefferson University
$29,313,609
Attributed
$40,965,998
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$83,348,260 · 23
By mechanism
P30$51,208,503 · 7
R01$30,643,302 · 11
R21$456,500 · 1
P20$393,997 · 1
R24$350,000 · 1
P01$295,958 · 2
Top collaborators
- Steven C. Almo12 shared
- Joan Weinberger Berman12 shared
- Brandon K Harvey5 shared
- Jonathan Karn5 shared
- Gary E. Landreth4 shared
- Richard M Ransohoff2 shared
- Shanye Yin2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Yuri Sykulev$9,058,653
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsIn VivoPreventCellsViralProgramsAntiretroviral TherapyResearch PersonnelBaseAcquired Immunodeficiency SyndromeMouse ModelIn VitroLinkCytokineInfectionDesignHiv-1ServicesSynergismStructureMedicineResponseCollegeLeadership
Grant awards (112)
ERC Einstein-Rockefeller-CUNY Center for AIDS research$2,249,998
P30 · FY2025 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$1,679,994
R01 · FY2025 · AI · contact PI
Developing and evaluating cell-specific lentivectors capable of selective in vivo generation of anti-HIV T cells to cure HIV$717,317
R01 · FY2025 · AI · contact PI
Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models$578,249
R01 · FY2025 · CA
ERC Einstein Rockefeller CUNY Center for AIDS Research$375,000
P30 · FY2025 · AI · contact PI
ERC Einstein-Rockefeller-CUNY Center for AIDS research$2,049,998
P30 · FY2024 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$839,997
R01 · FY2024 · AI · contact PI
Developing and evaluating cell-specific lentivectors capable of selective in vivo generation of anti-HIV T cells to cure HIV$734,317
R01 · FY2024 · AI · contact PI
Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models$578,249
R01 · FY2024 · CA
ERC Einstein-Rockefeller-CUNY Center for AIDS research$472,482
P30 · FY2024 · AI · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$466,431
P30 · FY2024 · AI · contact PI
Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-related Operations$350,000
R24 · FY2024 · OD · contact PI
ERC Einstein-Rockefeller-CUNY Center for AIDS Research$317,300
P30 · FY2024 · AI · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$317,300
P30 · FY2024 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$99,295
R01 · FY2024 · AI · contact PI
ERC Einstein-Rockefeller-CUNY Center for AIDS research$2,959,147
P30 · FY2023 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$839,997
R01 · FY2023 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2023 · DA
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission$829,213
R01 · FY2023 · AI · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$549,335
P30 · FY2023 · AI · contact PI
ERC Einstein-Rockefeller-CUNY Center for AIDS research$506,349
P30 · FY2023 · AI · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$506,349
P30 · FY2023 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$99,295
R01 · FY2023 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$19,349
R01 · FY2023 · AI · contact PI
ERC Einstein-Rockefeller-CUNY Center for AIDS research$3,603,724
P30 · FY2022 · AI · contact PI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection$839,997
R01 · FY2022 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2022 · DA
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission$829,213
R01 · FY2022 · AI · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$524,649
P30 · FY2022 · AI · contact PI
Einstein-Rockefeller-CUNY Center for AIDS Research$2,792,128
P30 · FY2021 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2021 · DA
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission$829,213
R01 · FY2021 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$752,263
R01 · FY2021 · DA
Administrative Core$748,590
P30 · FY2021 · AI · contact PI
Einstein-Rockefeller-CUNY Center for AIDS Research$2,894,381
P30 · FY2020 · AI · contact PI
Administrative Core$862,022
P30 · FY2020 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2020 · DA
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission$829,213
R01 · FY2020 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$754,479
R01 · FY2020 · DA
Einstein-Rockefeller-CUNY Center for AIDS Research$2,516,681
P30 · FY2019 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2019 · DA
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission$829,213
R01 · FY2019 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$756,652
R01 · FY2019 · DA
Administrative Core$442,644
P30 · FY2019 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$158,650
R01 · FY2019 · DA
Einstein-Rockefeller-CUNY Center for AIDS Research$1,126,413
P30 · FY2018 · AI · contact PI
Einstein-Rockefeller-CUNY Center for AIDS Research$793,947
P30 · FY2018 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$514,958
R01 · FY2018 · DA
Administrative Core$264,969
P30 · FY2018 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$243,823
R01 · FY2018 · DA
Administrative Core$178,020
P30 · FY2018 · AI · contact PI
Einstein-Rockefeller-CUNY Center for AIDS Research$1,498,120
P30 · FY2017 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$834,993
R01 · FY2017 · DA
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$714,043
R01 · FY2017 · DA
Administrative Core$417,007
P30 · FY2017 · AI · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$708,347
R01 · FY2016 · DA
Systems biology analysis of in vivo impact of substance abuse on HIV infection$575,524
R01 · FY2016 · DA · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$706,181
R01 · FY2015 · DA
Systems biology analysis of in vivo impact of substance abuse on HIV infection$353,903
R01 · FY2015 · DA · contact PI
Systems biology analysis of in vivo impact of substance abuse on HIV infection$252,787
R01 · FY2015 · DA · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$718,338
R01 · FY2014 · DA
Systems biology analysis of in vivo impact of substance abuse on HIV infection$615,930
R01 · FY2014 · DA · contact PI
Center for AIDS Research (CFAR)$834,723
P30 · FY2013 · AI · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$734,339
R01 · FY2013 · DA
Systems biology analysis of in vivo impact of substance abuse on HIV infection$547,019
R01 · FY2013 · DA · contact PI
BSL3/Virology Core$114,339
P30 · FY2013 · AI · contact PI
Administrative Core$109,356
P30 · FY2013 · AI · contact PI
Systems biology analysis of in vivo impact of substance abuse on HIV infection$34,591
R01 · FY2013 · DA · contact PI
Center for AIDS Research (CFAR)$1,669,445
P30 · FY2012 · AI · contact PI
Systems biology analysis of in vivo impact of substance abuse on HIV infection$575,758
R01 · FY2012 · DA · contact PI
BSL3/Virology Core$225,468
P30 · FY2012 · AI · contact PI
Administrative Core$221,160
P30 · FY2012 · AI · contact PI
Center for AIDS Research (CFAR)$2,311,544
P30 · FY2011 · AI · contact PI
Administrative Core$485,477
P30 · FY2011 · AI · contact PI
BSL3/Virology Core$288,020
P30 · FY2011 · AI · contact PI
Analysis of in vivo Effects of HIV, LPS and Buprenorphine on the Brain Proteome$115,378
P20 · FY2011 · DA · contact PI
Center for AIDS Research (CFAR)$1,686,309
P30 · FY2010 · AI · contact PI
Mechanisms of in vivo protection from HIV infection$403,043
R01 · FY2010 · AI · contact PI
Administrative Core$354,164
P30 · FY2010 · AI · contact PI
BSL3/Virology Core$210,116
P30 · FY2010 · AI · contact PI
Analysis of in vivo Effects of HIV, LPS and Buprenorphine on the Brain Proteome$127,332
P20 · FY2010 · DA · contact PI
Center for AIDS Research (CFAR)$1,902,244
P30 · FY2009 · AI · contact PI
Mechanisms of in vivo protection from HIV infection$407,115
R01 · FY2009 · AI · contact PI
Administrative Core$399,516
P30 · FY2009 · AI · contact PI
BSL3/Virology Core$237,020
P30 · FY2009 · AI · contact PI
Structural Analysis , mutation and therapeutic use of TCRs from HIV-specific CTLs$207,500
R21 · FY2009 · AI · contact PI
Analysis of in vivo Effects of HIV, LPS and Buprenorphine on the Brain Proteome$151,287
P20 · FY2009 · DA · contact PI
Center for AIDS Research (CFAR)$1,907,591
P30 · FY2008 · AI · contact PI
Mechanisms of in vivo protection from HIV infection$407,115
R01 · FY2008 · AI · contact PI
Administrative Core$271,662
P30 · FY2008 · AI · contact PI
BSL3/Virology Core$257,627
P30 · FY2008 · AI · contact PI
Structural Analysis , mutation and therapeutic use of TCRs from HIV-specific CTLs$249,000
R21 · FY2008 · AI · contact PI
Center for AIDS Research (CFAR)$1,590,143
P30 · FY2007 · AI · contact PI
Mechanisms of in vivo protection from HIV infection$415,000
R01 · FY2007 · AI · contact PI
Viral Immunoregulatory Genes in Beta Cells to Treat Diabetes$295,958
P01 · FY2007 · DK · contact PI
Center for AIDS Research (CFAR)$1,582,244
P30 · FY2006 · AI · contact PI
Center for AIDS Research (CFAR)$1,833,602
P30 · FY2005 · AI
Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics$375,750
R01 · FY2005 · AI
Center for AIDS Research (CFAR)$1,520,542
P30 · FY2004 · AI
Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics$375,750
R01 · FY2004 · AI
HIV + Women in Cape Town Behavioral Intervention$270,203
P30 · FY2004 · AI
Center for AIDS Research (CFAR)$1,493,004
P30 · FY2003 · AI
Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics$375,750
R01 · FY2003 · AI
TRANSGENIC MICE--MODEL FOR STUDYING HIV INFECTION OF THE$321,470
R01 · FY2003 · NS
Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics$375,844
R01 · FY2002 · AI
TRANSGENIC MICE--MODEL FOR STUDYING HIV INFECTION OF THE$316,058
R01 · FY2002 · NS
SV40 based HIV gene therapy in SCID-hu mice$0
P01 · FY2002 · AI
Transgenic/SCID-hu Mouse Model to Study HIV Therapeutics$358,031
R01 · FY2001 · AI
TRANSGENIC MICE--MODEL FOR STUDYING HIV INFECTION OF THE$310,800
R01 · FY2001 · NS
SV40 based HIV gene therapy in SCID-hu mice$0
P01 · FY2001 · AI
TRANSGENIC MICE--MODEL FOR STUDYING HIV INFECTION OF THE$306,537
R01 · FY2000 · NS
SV40 based HIV gene therapy in SCID-hu mice$0
P01 · FY2000 · AI